C9254 HCPCS Level II code: Injection, lacosamide, 1 mg
C9254 is the HCPCS code for “Injection, lacosamide, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
C9254Injection, lacosamide, 1 mg
Short description: Injection, lacosamide
HCPCS · United States
Medicare details
The indicators CMS publishes with C9254 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Other medical items or services
- BETOS category
- Other drugs
- Coverage statute
- 621MMA
- Added
- Jan 1, 2010
Where C9254 sits
- 1C codesOutpatient prospective payment system
- 2Active code C9254Injection, lacosamide, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code C9254 mean?
C9254 is the HCPCS code for “Injection, lacosamide, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover C9254?
CMS lists C9254’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9254
All C codesC9173Injection, filgrastim-txid (nypozi), biosimilar, 1 microgramC9174Injection, datopotamab deruxtecan-dlnk, 1 mgC9175Injection, treosulfan, 50 mgC9176Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study doseC9248Injection, clevidipine butyrate, 1 mgC9250Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 mlC9257Injection, bevacizumab, 0.25 mgC9275Injection, hexaminolevulinate hydrochloride, 100 mg, per study doseC9285Lidocaine 70 mg/tetracaine 70 mg, per patchC9290Injection, bupivacaine liposome, 1 mgC9293Injection, glucarpidase, 10 unitsC9300Injection, indigotindisulfonate sodium, 1 mg